NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced the appointment of Abraham Ceesay as Vice President of Marketing and Operations. In this role, Mr. Ceesay will develop and lead all aspects of the ZerenexTM launch strategy and execution, including brand planning, forecasting and analysis, marketing operations and patient access programs. The Company’s new drug application for Zerenex (ferric citrate coordination complex) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014.
Help employers find you! Check out all the jobs and post your resume.
